Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY23
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY18
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY18
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY18
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stock
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
5827.75 | 1,70,800 Cr | 62.42 | 11.08 | 0.47 | 16.12 | 20.29 | 13.66 | ||
4011.95 | 1,41,579 Cr | 59.69 | 16.76 | 0.14 | 25.33 | 27.37 | 14.64 | ||
1312.40 | 1,13,075 Cr | 19.64 | 3.14 | 0.59 | 16.03 | 18.66 | 10.16 | ||
1201.10 | 1,05,662 Cr | 21.35 | 3.21 | 1.22 | 16.53 | 21.05 | 11.32 | ||
2326.80 | 1,05,247 Cr | 21.44 | 5.36 | 0.52 | 22.03 | 21.92 | 13.94 | ||
2043.00 | 93,710 Cr | 47.47 | 6.13 | 0.00 | 11.45 | 12.34 | 6.26 | ||
864.25 | 91,693 Cr | 17.61 | 3.62 | 1.21 | 19.44 | 19.08 | 10.52 | ||
| Median: 7 Co. | — | 2043.00 | 1,05,662 Cr | 21.44 | 5.36 | 0.52 | 16.53 | 20.29 | 11.32 |
Torrent Pharmaceuticals is an India‑headquartered, vertically integrated pharmaceutical company focused on branded chronic and sub‑chronic therapies, with a diversified international presence across the US, Europe (Germany) and Latin America (Brazil) and over 15 country subsidiaries supporting formulation manufacturing, R&D and commercial operations for both regulated and emerging markets.
In Q3 FY26 Torrent reported consolidated revenues of INR 3,303 crore, up 18% year‑on‑year, with Operating EBITDA of INR 1,088 crore and an operating margin of 32.9%. Branded markets contributed roughly 75% of revenues; India grew 14% and Brazil grew 27%, while the U.S. and Germany contributed double‑digit and modest growth respectively amid some supply constraints.
Torrent acquired a controlling stake in JB Pharma in January and began line‑by‑line consolidation; management expects INR 400–450 crore of cost synergies over 2–3 years (20% in year one, majority thereafter) and a 6–9 month timeline to integrate post NCLT merger, making the JB acquisition a material near‑term strategic catalyst for the company.
Brazil represents a high‑conviction growth opportunity with a prioritized Semaglutide (GLP‑1) filing; management reports ANVISA prioritization and a 60‑molecule pipeline, but cautions on unpredictable approval timing and potential pricing erosion, which could meaningfully influence Brazilian revenue upside upon launch.
Near‑term operational risks include regulatory and third‑party supplier disruptions in Germany that depressed constant‑currency sales; the U.S. business is small but supported by a launch pipeline with management targeting annualized U.S. revenues near $200 million over the medium term, contingent on timely approvals and competitive dynamics.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,41,579 Cr
Low Risk
59.7
33.1
2.4
16.8
4,479.70
3,101.00
Sales CAGR
Profit CAGR
ROE
ROCE
Torrent Pharmaceuticals Ltd (TORNTPHARM) is currently trading at 4,261.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Torrent Pharmaceuticals is an India‑headquartered, vertically integrated pharmaceutical company focused on branded chronic and sub‑chronic therapies, with a diversified international presence across the US, Europe (Germany) and Latin America (Brazil) and over 15 country subsidiaries supporting formulation manufacturing, R&D and commercial operations for both regulated and emerging markets. In Q3 FY26 Torrent reported consolidated revenues of INR 3,303 crore, up 18% year‑on‑year, with Operating EBITDA of INR 1,088 crore and an operating margin of 32.9%. Branded markets contributed roughly 75% of revenues; India grew 14% and Brazil grew 27%, while the U.S. and Germany contributed double‑digit and modest growth respectively amid some supply constraints. Torrent acquired a controlling stake in JB Pharma in January and began line‑by‑line consolidation; management expects INR 400–450 crore of cost synergies over 2–3 years (20% in year one, majority thereafter) and a 6–9 month timeline to integrate post NCLT merger, making the JB acquisition a material near‑term strategic catalyst for the company. Brazil represents a high‑conviction growth opportunity with a prioritized Semaglutide (GLP‑1) filing; management reports ANVISA prioritization and a 60‑molecule pipeline, but cautions on unpredictable approval timing and potential pricing erosion, which could meaningfully influence Brazilian revenue upside upon launch. Near‑term operational risks include regulatory and third‑party supplier disruptions in Germany that depressed constant‑currency sales; the U.S. business is small but supported by a launch pipeline with management targeting annualized U.S. revenues near $200 million over the medium term, contingent on timely approvals and competitive dynamics.
Over the past 52 weeks, Torrent Pharmaceuticals Ltd has traded between a low of ₹3,101.00 and a high of ₹4,479.70. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Torrent Pharmaceuticals Ltd has a market capitalization of approximately 1,41,578.50. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Torrent Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 59.69 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,41,578.50 Cr, Torrent Pharmaceuticals Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Torrent Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Torrent Pharmaceuticals Ltd is 59.69. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
It is a procedural clarification dated March 24, 2026, issued by the NCLT Ahmedabad Bench to clarify the main order that sanctioned the amalgamation.
The USFDA inspection at the Dahej, Gujarat facility, conducted from January 19-23, 2026, concluded with zero observations, indicating full compliance with regulatory standards.
It is a clarifying document issued on March 24, 2026, to correct or clarify the NCLT's original order that approved the amalgamation of J.B. Chemicals into Torrent Pharmaceuticals.
It is a ₹10,000 crore, five-year mission aimed at making India a global biopharmaceutical manufacturing hub by supporting domestic production of biologics, upgrading research institutes, and creating a large network of clinical trial sites.
Merger approval
At an NCLT‑convened meeting on April 28, 2026 held via VC, Torrent Pharmaceuticals' equity shareholders approved the Scheme of Amalgamation with J.B. Chemicals & Pharmaceuticals; voting showed ~99.33% in favour by number/value.
Merger/Amalgamation Approval
At an NCLT‑convened meeting on April 28, 2026, equity shareholders of Torrent Pharmaceuticals approved the Scheme of Amalgamation to merge J.B. Chemicals & Pharmaceuticals into Torrent, with the requisite majority via remote e‑voting and at‑meeting voting.
Bearish
5
Neutral
4
Bullish
5
Bearish
5
Neutral
4
Bullish
37
Bearish
0
Neutral
0
Bullish
32
